Abstract
Although a great body of evidence is available on the immunosuppressive strategies employed by tumors in order to grow, cancer patients are not considered immunosuppressed individuals. Chemotherapy used in different cancer treatments frequently leads to leucopenia and affects immune responses. Tumors of the immune system can also cause immune alterations, due to their very nature. However, in the absence of preventive routine exams, patients can bear tumors for rather long periods of time without any specific indication, not being particularly prone to contracting infectious diseases compared to cancer free individuals. In this review, we analyze the existing data on the effects of tumors on the immune system of cancer patients. An interesting pattern emerges, suggesting that immunosuppression exerted by tumors is mainly local, rather than systemic. However, some alterations in DCs of cancer patients have been recently described, indicating the interactions between tumor and immune cells may be more complex than previously imagined. This has important implications of the design of anti-tumor therapies as well as in patient quality of life.
Keywords: cancer, immunity, inflammation, immunotherapy, immunosuppressive, chemotherapy, leucopenia, anti-tumor therapies, cytokines, NKG2D
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: The Immune System of Cancer Patients
Volume: 10 Issue: 4
Author(s): Carolina Torronteguy and Ana Paula Souza e Cristina Bonorino
Affiliation:
Keywords: cancer, immunity, inflammation, immunotherapy, immunosuppressive, chemotherapy, leucopenia, anti-tumor therapies, cytokines, NKG2D
Abstract: Although a great body of evidence is available on the immunosuppressive strategies employed by tumors in order to grow, cancer patients are not considered immunosuppressed individuals. Chemotherapy used in different cancer treatments frequently leads to leucopenia and affects immune responses. Tumors of the immune system can also cause immune alterations, due to their very nature. However, in the absence of preventive routine exams, patients can bear tumors for rather long periods of time without any specific indication, not being particularly prone to contracting infectious diseases compared to cancer free individuals. In this review, we analyze the existing data on the effects of tumors on the immune system of cancer patients. An interesting pattern emerges, suggesting that immunosuppression exerted by tumors is mainly local, rather than systemic. However, some alterations in DCs of cancer patients have been recently described, indicating the interactions between tumor and immune cells may be more complex than previously imagined. This has important implications of the design of anti-tumor therapies as well as in patient quality of life.
Export Options
About this article
Cite this article as:
Torronteguy Carolina and Paula Souza e Cristina Bonorino Ana, The Immune System of Cancer Patients, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (4) . https://dx.doi.org/10.2174/187152311797928126
DOI https://dx.doi.org/10.2174/187152311797928126 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumor Specific Novel Taxoid-Monoclonal Antibody Conjugates
Current Medicinal Chemistry Biocompatibility and Solubility of Fe3O4-BSA Conjugates with Human Blood
Current Nanoscience Anti-Tumor Activity of Non-Nucleosidic Reverse Transcriptase Inhibitors
Current Pharmaceutical Design Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine
Current Pharmaceutical Design The Cytoplasmic Rhodopsin-Protein Interface: Potential for Drug Discovery
Current Drug Targets Cellulitis-Like Sweet Syndrome Preceding Multiple Myeloma. A Case Report
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Therapeutic Potential of microRNA Against Th2-associated Immune Disorders
Current Topics in Medicinal Chemistry Nanobiotechnology and Nanostructured Therapeutic Delivery Systems
Recent Patents on Biomedical Engineering (Discontinued) Bcl-2 Family Proteins as Therapeutic Targets
Current Pharmaceutical Design Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Monoclonal Antibodies Carried in Drug Delivery Nanosystems as a Strategy for Cancer Treatment
Current Medicinal Chemistry Selective Cyclooxygenase-2 Inhibitors and Non-small Cell Lung Cancer
Current Medicinal Chemistry MGMT Epigenetics: The Influence of Gene Body Methylation and Other Insights Derived from Integrated Methylomic, Transcriptomic, and Chromatin Analyses in Various Cancer Types
Current Cancer Drug Targets CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Association Between miR-146a rs2910164 Polymorphism and Breast Cancer Susceptibility: An Updated Meta-Analysis of 9545 Cases and 10030 Controls
MicroRNA Multifunctional Radiolabeled Nanoparticles for Targeted Therapy
Current Medicinal Chemistry Polyphenols in Disease: from Diet to Supplements
Current Pharmaceutical Biotechnology